These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29459211)

  • 1. A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.
    Rogeberg O; Bergsvik D; Phillips LD; van Amsterdam J; Eastwood N; Henderson G; Lynskey M; Measham F; Ponton R; Rolles S; Schlag AK; Taylor P; Nutt D
    Int J Drug Policy; 2018 Jun; 56():144-152. PubMed ID: 29459211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use.
    Rolles S; Schlag AK; Measham F; Phillips L; Nutt D; Bergsvik D; Rogeberg O
    Int J Drug Policy; 2021 May; 91():103180. PubMed ID: 33640213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing options for cannabis law reform: A Multi-Criteria Decision Analysis (MCDA) with stakeholders in New Zealand.
    Wilkins C; Rychert M; Queirolo R; Lenton SR; Kilmer B; Fischer B; Decorte T; Hansen P; Ombler F
    Int J Drug Policy; 2022 Jul; 105():103712. PubMed ID: 35537275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prohibition, regulation or laissez faire: The policy trade-offs of cannabis policy.
    Rogeberg O
    Int J Drug Policy; 2018 Jun; 56():153-161. PubMed ID: 29636224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six policy lessons relevant to cannabis legalization.
    Shover CL; Humphreys K
    Am J Drug Alcohol Abuse; 2019; 45(6):698-706. PubMed ID: 30870053
    [No Abstract]   [Full Text] [Related]  

  • 6. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
    Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
    Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Australian drug harms ranking study.
    Bonomo Y; Norman A; Biondo S; Bruno R; Daglish M; Dawe S; Egerton-Warburton D; Karro J; Kim C; Lenton S; Lubman DI; Pastor A; Rundle J; Ryan J; Gordon P; Sharry P; Nutt D; Castle D
    J Psychopharmacol; 2019 Jul; 33(7):759-768. PubMed ID: 31081439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critique of cannabis legalization proposals in Canada.
    Kalant H
    Int J Drug Policy; 2016 Aug; 34():5-10. PubMed ID: 27292414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The New Cannabis Policy Taxonomy on APIS: Making Sense of the Cannabis Policy Universe.
    Klitzner MD; Thomas S; Schuler J; Hilton M; Mosher J
    J Prim Prev; 2017 Jun; 38(3):295-314. PubMed ID: 28477299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications.
    Hall W; Kozlowski LT
    Addiction; 2018 Apr; 113(4):595-601. PubMed ID: 28544367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis.
    van Amsterdam J; Peters GY; Pennings E; Blickman T; Hollemans K; Breeksema JJJ; Ramaekers JG; Maris C; van Bakkum F; Nabben T; Scholten W; Reitsma T; Noijen J; Koning R; van den Brink W
    J Psychopharmacol; 2021 May; 35(5):537-546. PubMed ID: 33530825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From prohibition to regulation: A comparative analysis of the emergence and related outcomes of new legal cannabis policy models (Colorado, Washington State and Uruguay).
    Obradovic I
    Int J Drug Policy; 2021 May; 91():102590. PubMed ID: 31740177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When prohibition works: Comparing fireworks and cannabis regulations, markets, and harms.
    Caulkins JP; Reimer KV
    Int J Drug Policy; 2023 Aug; 118():104081. PubMed ID: 37315476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenges in developing a rational cannabis policy.
    Hall W; Lynskey M
    Curr Opin Psychiatry; 2009 May; 22(3):258-62. PubMed ID: 19293714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations.
    Fischer B; Daldegan-Bueno D; Boden JM
    Drug Alcohol Rev; 2020 Jul; 39(5):555-567. PubMed ID: 32436274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A History of United States Cannabis Law.
    Patton DV
    J Law Health; 2020; 34(1):1-29. PubMed ID: 33449455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mapping regulatory models for medicinal cannabis: a matrix of options.
    Belackova V; Shanahan M; Ritter A
    Aust Health Rev; 2018 Aug; 42(4):403-411. PubMed ID: 28553995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Canadian Cannabis Act legalizes and regulates recreational cannabis use in 2018.
    Cox C
    Health Policy; 2018 Mar; 122(3):205-209. PubMed ID: 29429644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential impact of cannabis legalization on the development of cannabis use disorders.
    Budney AJ; Borodovsky JT
    Prev Med; 2017 Nov; 104():31-36. PubMed ID: 28668544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Over and under-regulation in the Colorado Cannabis industry - A data-analytic perspective.
    Yates D; Speer J
    Int J Drug Policy; 2018 Sep; 59():63-66. PubMed ID: 30015248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.